How effective is the targeted drug gilteritinib? Can leukemia be cured?

Gilteritinibis a fms-like tyrosine kinase-3 Inhibitors of multiple receptor tyrosine kinases including (Flt-3), used to treat relapsed or refractory acute myeloid leukemia carrying Flt-3 mutations.

In a Phase 3 trial, adults with relapsed or refractory FLT3-mutated in a 2:1 ratioAMLreceived gilitinib (dose 120mg/day) or salvage chemotherapy. The two primary endpoints were overall survival and the percentage of patients with complete response and complete or partial hematologic recovery. Secondary endpoints included event-free survival and the percentage of patients with complete response. Results:Among 371 eligible patients, 247 were randomly assigned to the giritinib group, and 124 were assigned to the salvage chemotherapy group. The median overall survival of the geritinib group was significantly longer than that of the chemotherapy group (9.3 months vs. 5.6 months); the hazard ratio for death was 0.64; 95% an>Confidence interval[CI], 0.49 to 0.83; P<0.001). The median event-free survival was 2.8 months in the geritinib group and 0.7 months in the chemotherapy group.The hazard ratio for treatment failure or death was 0.79; the 95% confidence interval was 0.58 to 1.09). The percentage of patients with complete response and complete or partial hematologic recovery was 34.0% in the gilitinib group and 15.3% in the chemotherapy group (risk difference, 18.6percentage points;95%The confidence interval is9.8to27.4) span>; the percentages of complete responses were 21.1% and 10.5% (Risk difference, 10.6 span>percentage points;95%confidence interval is 2.8to18.4). In analyzes adjusting for duration of treatment, the incidence of grade 3 or higher adverse events and serious adverse events was lower in the geritinib group than in the chemotherapy group; the most common adverse events of grade 3 or higher in the geritinib group were They were febrile neutropenia (45.9%), anemia (40.7%) and thrombocytopenia (22.8%). Conclusion:In relapsed or refractory patients, compared with salvage chemotherapy, giritinib can significantly prolong survival and increase the percentage of patients with remissionFLT3mutated acute myeloid leukemia.

Giritinib has a good therapeutic effect on acute refractory acute myeloid leukemia with FLT3 mutation, and it needs to be taken until the patient cannot benefit or develops intolerable side effects. The most common adverse reactions of giritinib (≥20%) are elevated transaminases, myalgia, arthralgia, fatigue and discomfort, fever, mucositis, edema, rash, non-infectious diarrhea, dyspnea, nausea, cough, constipation, eye disease, headache, dizziness, hypotension, vomiting and renal damage. There are many versions of generic drugs, priced at about three to four thousand per box. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.